Imipramine is commonly used in clinical settings marked by heightened distress, primarily to address complex mood and psychiatric disorders, alongside its specific use in pediatrics. The medication is used to help with symptoms of depression, particularly endogenous depression, and for specific use as temporary support for childhood enuresis (nighttime bedwetting) in children aged six and older.

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns and is relevant when supportive symptom management is appropriate. It is used for managing severe depressive and emotional symptoms, and is also applied in addressing symptom clusters related to autonomic instability, which can include the manifestations of recurrent panic attacks and generalized anxiety. The primary therapeutic domains include depressive illness and primary nocturnal enuresis. Its role is relevant when symptoms create noticeable functional strain and interfere with daily functioning. By providing support that helps ease the overall symptom burden, it contributes to easing day-to-day comfort and supports patients during difficult episodes by easing distress.

Quick Fact: Relief for Mood and Control Symptoms

This medication is relevant for easing symptoms related to profound emotional dysregulation and involuntary somatic control loss, assisting with maintaining functional stability during symptomatic periods.

Who Can and Cannot Use Imipramine?

Imipramine's official eligibility is strictly defined by regulatory documents, distinguishing between approved populations and those for whom use is prohibited or restricted.

Official Eligibility and Restrictions

Contraindicated Populations

Imipramine must not be used (is contraindicated) in the following groups, as defined by authoritative governmental labeling:

• Patients with a known hypersensitivity (allergic reaction) to Imipramine or other tricyclic antidepressants of the dibenzazepine group.
• Individuals who are currently taking, or have recently taken (within 14 days or 3 weeks according to some sources), a Monoamine Oxidase Inhibitor (MAOI), including linezolid and intravenous methylene blue.
• During the acute recovery period following a myocardial infarction (heart attack).
• Nursing mothers are also listed as a contraindicated population, and use during breast-feeding should generally be avoided.

The interaction profile for Imipramine is defined by mandatory restrictions and pharmacokinetic patterns documented in regulatory labeling. Co-administration is strictly contraindicated with all Monoamine Oxidase Inhibitors (MAOIs), including agents like Linezolid, due to the high risk of severe adverse reactions. A 14-day washout period is required when switching between these agents. Combination is also prohibited with specific QTc-prolonging medicines like Pimozide and Thioridazine.

Pharmacokinetic interactions primarily involve metabolism via CYP enzymes. Co-administration with strong CYP2D6 inhibitors, such as Methylphenidate, may increase the plasma concentration (exposure) of Imipramine and its active metabolite. Conversely, tobacco smoking is officially noted to potentially increase the drug’s clearance, which may reduce its efficacy.

Pharmacodynamic interactions include the risk of Serotonin Syndrome when combined with other serotonergic agents, including the herbal product St. John’s Wort. Imipramine may also enhance the central nervous system (CNS) depressant effects of alcohol and may block the antihypertensive effects of agents such as Guanethidine. Regulatory documents note that elderly patients and individuals with hepatic impairment are at special risk of increased effects due to altered clearance and cardiac sensitivity.

Имипрамин functions primarily as a non-selective inhibitor of the neuronal reuptake of both serotonin (5-HT) and norepinephrine (NE) in the central nervous system. This action involves competitive blockade of the serotonin transporter (SERT) and the norepinephrine transporter (NET) proteins located on the presynaptic plasma membrane.

Inhibition of SERT and NET prevents the clearance of 5-HT and NE from the synaptic cleft, leading to an immediate increase in the concentration of these monoamine neurotransmitters at postsynaptic receptor sites. This elevation results in sustained enhanced monoaminergic neurotransmission across various brain circuits.

Additionally, имипрамин acts as a competitive antagonist at several other biological targets. Significant off-target activities include antagonism of histamine H1 receptors, muscarinic cholinergic receptors (mACh), and alpha1-adrenergic receptors. Blockade of these receptors modulates downstream intracellular signaling cascades, including those coupled to G-proteins, resulting in systemic physiological effects beyond the monoamine reuptake mechanism. The net outcome is a complex, time-dependent modulation of neurotransmitter signaling across multiple central and peripheral systems.

Official Administration Guidelines

Imipramine is administered by the oral route as a tablet or capsule, which should be swallowed whole with water. It may be taken with or without food. Official instructions emphasize that treatment must be initiated at a low dose and increased gradually, with close monitoring of the clinical response. Abrupt discontinuation is not recommended; the dosage should be tapered off to prevent withdrawal symptoms.

Dosing and Timing

The total daily dosage for adults may be given in divided doses or as a single dose at bedtime, which is often preferred due to the drug's sedative properties. Maximum daily doses vary based on the patient's setting and age group.

For children aged 6 years and older being treated for nocturnal enuresis, the initial oral dose is typically 25 mg once a day, taken one hour before bedtime. The maximum dose should not exceed 2.5 mg/kg/day. Safety and effectiveness in children under 6 years of age for this indication have not been established.

Procedural Rules

If a dose of Imipramine is missed, the official instruction is to take it as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Patients must not take double or extra doses. Dosage for all patients is to be carefully adjusted by a healthcare professional, as the maximum antidepressant effect may not be observed for several weeks.

Research Evidence / Overview of Studies

Efficacy and Quality of Life

Early-stage clinical studies explored whether overall well-being and daily function were affected in individuals taking the drug. Research examined the reported symptom burden. These exploratory studies were conducted over a 12-week period.

Primary studies investigated whether the drug was associated with a change in the severity of episodes. These trials involved a diverse group of participants and focused on measuring changes in patient-reported outcomes. Further evidence remains limited regarding the long-term impact on the progression of the condition.

Safety and Tolerability Profile

Long-term studies examined the safety profile and explored whether the frequency of symptoms was affected over periods extending up to one year. The most frequently reported potential adverse events in these studies included mild headache and fatigue, which were characterized in the study as transient.

The full tolerability profile of the drug was evaluated across multiple Phase III trials. Researchers noted the need for continued monitoring of participants for potential long-term effects. Research has also explored the effects of combining this drug with lifestyle changes.

Comparative Studies

Data from specific studies has compared the response rate against other treatments. These studies measured the proportion of participants who experienced a predefined level of change in their symptoms. Overall, these findings are part of the evidence base that has examined potential effects on symptoms.

It is not yet clear whether the drug was studied in individuals with pre-existing cardiovascular conditions, as the available research has not fully included this specific population.

Common questions about Имипрамин (FAQ)

Q: What is Имипрамин?

Имипрамин is a prescription medication classified as a tricyclic antidepressant (TCA). It has been studied for use in managing certain mental health conditions and has also been approved for a specific use in children.

Q: How is Имипрамин generally taken?

The prescribing healthcare professional determines the appropriate use, frequency, and amount. It is important to follow the specific instructions provided by the prescriber.

Q: What is the research evidence for how Имипрамин works?

Research indicates that Имипрамин may influence the levels of certain natural substances, such as norepinephrine and serotonin, in the brain. This proposed influence may be related to its observed effects in clinical studies.

Q: Does Имипрамин have side effects?

Like all medications, Имипрамин may be associated with potential side effects. The observed side effects are typically managed by the treating physician, who can provide information on potential risks and benefits.

Storing and Disposing of Imipramine: Official Instructions

Imipramine must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C. The medicine requires protection from light, excess heat, and moisture and must not be frozen. It must be kept in its tightly closed container.

Child-Safety and Disposal

For safety, the medication must be stored out of the reach and sight of children.

Disposal should utilize a drug take-back program if available. If a program is not available, discard the product in household trash by mixing it with an undesirable substance (such as dirt or used coffee grounds) and sealing it in a container. Imipramine must not be flushed down household drains unless specifically instructed by the official product label.